Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate

      This paper is only available as a PDF. To read, Please Download here.


      Combined treatment of hyperlipidaemia with the nicotinic acid derivative pentaerythritol tetranicotinate (Perycit®) and clofibrate or the clofibrate analogue cholesolvin has been used in 26 ambulant patients with different types of hyperlipidaemia (types IIa, IIb and IV).
      The treatment started with Perycit® 1g × 3 daily followed by cholesolvin 1 g × 2 or vice versa. The two drugs were then given together in the same doses as before and finally clofibrate was substituted for cholesolvin.
      The two types of drugs, Perycit® and cholesolvin or clofibrate respectively, were found to have additive synergistic effects on plasma cholesterol as well as on plasma triglyceride concentration. There was no difference between cholesolvin and clofibrate in this respect.
      The usual side effects like flush were seen with Perycit®, but the combined treatment with Perycit® and cholesolvin or clofibrate produced no additional adverse reactions.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Altschul R.
        • Hoffer A.
        • Stephen J.D.
        Influence of nicotinic acid on serum cholesterol in man.
        Arch. Biochem. 1955; 54: 558
        • Olsson A.G.
        • Orö L.
        • Rössner S.
        Clinical and metabolic effects of pentaerythritol tetranicotinate (Perycit) and a comparison with plain nicotinic acid.
        Atherosclerosis. 1974; 19: 61
        • Carlson L.A.
        • Orö L.
        • Östman J.
        Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia.
        Acta Med. Scand. 1968; 457: 183
        • Carlson L.A.
        • Orö L.
        • Östman J.
        Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia during the first week of treatment.
        J. Atheroscler. Res. 1968; 8: 66
        • Carlson L.A.
        The effect of nicotinic acid treatment on the chemical composition of plasma lipoprotein classes in man.
        in: Holmes W.L. Carlson L.A. Paoletti R. Drugs Affecting Lipid Metabolism, Advances in Experimental Medicine and Biology. Vol. 4. Plenum Press, New York, N. Y.1969: 327
        • Orö L.
        Indikationer för nikotinsyra och nikotinsyrederivat.
        Läkartidningen. 1970; 67: 63
        • Sigroth K.
        Pentaerythritol tetranicotinate (Perycit®) in treatment of hypercholesterolaemia.
        Acta Med. Scand. 1968; 184: 269
        • Grundy S.M.
        • Ahrens Jr., E.H.
        • Salen G.
        • Schreibman P.H.
        • Nestel P.J.
        Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia.
        J. Lipid Res. 1972; 13: 531
        • Wilson D.E.
        • Lees R.S.
        Reciprocal changes in the concentrations of very low and low density lipoproteins in man.
        J. Clin. Invest. 1972; 51: 1051
        • Hansen P.F.
        Kombinationsbehandling ved hyperlipidaemi (Ateroskleros-nikotinsyraterapi (10).
        Läkartidningen. 1971; 68: 1769
        • Nakanishi M.
        • Kobayakawa T.
        • Okada T.
        • Gotoh K.
        Studies on antiatherosclerotic agents, Part II (Experimental studies of 1,3-propandiolbis-(α-p-chlorophenoxyisobutyrate) (CLY-503) for antiatherosclerotic agents).
        Yakugaku Zasshi (J. Pharm. Soc. Jap.). 1970; 90: 926
        • Kusukawa R.
        • Shinoyama S.
        • Watabe S.
        • Shirahama Y.
        • Kin U.
        Effects of CLY-503 on hyperlipidemia.
        Shinryo to Shiyaku, Med. Consult. New Remedies. 1971; 8: 617
        • Katori R.
        Clinical effects of CLY-503.
        Shinryo to Shinyaku (Med. Consult. and New Remedies). 1971; 8: 625
        • Block W.D.
        • Jarrett K.J.
        • Leoine B.
        Use of a single color reagent to improve the automated determination of serum total cholesterol.
        in: Skeggs L.T. Automation in Analytical Chemistry. Vol. 1. Medical Inc., New York, N.Y.1965: 345-347
        • Carlson L.A.
        Determination of serum triglycerides.
        J. Atheroscler. Res. 1963; 3: 334
        • Kessler G.
        • Lederer H.
        Fluorimetric measurement of triglycerides.
        in: Skeggs L.T. Automation in Analytical Chemistry. Vol. 1. Medical Inc., New York, N.Y.1965: 341-344
        • Hatch F.T.
        • Lees R.S.
        Practical methods for plasma lipoprotein analysis.
        Advan. Lipid Res. 1968; 6: 1
        • Beaumont J.-L.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of hyperlipidaemias and hyperlipoproteinaemias.
        Bull. Wld. Hlth. Org. 1970; 43: 891
        • Snedecor G.W.
        Statistical Methods. The Iowa State University Press, Ames, Iowa1964